<DOC>
	<DOCNO>NCT01532648</DOCNO>
	<brief_summary>This study compare efficacy safety budesonide MMX 9 mg versus placebo add-on therapy exist oral 5-ASA regimen induction remission patient active , mild moderate ulcerative colitis ( UC ) .</brief_summary>
	<brief_title>Randomized Placebo Controlled Trial Budesonide Multi-Matrix System ( MMX® ) 9 mg Patients With Ulcerative Colitis Currently 5-Aminosalicylic Acid ( 5-ASA ) .</brief_title>
	<detailed_description>Eligible patient randomize one follow two treatment arm : 1 . Budesonide MMX 9 mg ( one tablet ) 2 . Placebo ( tablet indistinguishable budesonide MMX 9 mg tablet ) The assign study drug take single oral tablet morning breakfast . In addition study drug , patient continue exist background oral 5-ASA regimen treatment period .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Aminosalicylic Acid</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>1 . Age 18 75 year , inclusive . 2 . Established diagnosis UC , base clinical history , exclusion infectious cause , characteristic endoscopic histologic finding . 3 . Active mild moderate UC UCDAI score ≥ 4 ≤ 10 , mucosal appearance score ≥ 1 , physician 's rating disease activity 1 2 . 4 . Experiencing active UC ( flare ) despite therapeutic dose oral 5ASA ( e.g. , mesalamine ≥ 2.4 g/day ≥ 6 week prior randomization , equivalent ) . At screening , photographic evidence active UC base mucosal appearance must obtain . 5 . Women childbearing potential men reproductive potential must willing use acceptable form contraception . . 6 . Able comprehend full nature purpose study , include possible risk side effect , also able comply requirement study . Must able understand voluntarily sign informed consent prior study procedure . 1 . Limited distal proctitis ( anal verge 15 cm pectineal line ) . 2 . Severe UC ( UCDAI &gt; 10 physician global assessment [ PGA ] &gt; 2 ) , nonactive UC ( UCDAI &lt; 4 ) . 3 . Infectious colitis recent history infectious colitis ( within 30 day Screening ) . 4 . Active malignancy carcinoma situ within last 5 year ( treat nonmelanoma skin cancer exclusionary ) . 5 . Active ulcer bleed disorder may affect evaluation blood stool . 6 . Evidence history toxic megacolon bowel resection . 7 . Crohn 's disease indeterminate colitis . 8 . Known hypersensitivity budesonide ingredient budesonide MMX tablets 9 . Active tuberculosis active systemic local bacterial , fungal , viral infection 10 . Liver cirrhosis , evident hepatic renal disease insufficiency , significant impairment biohumoral parameter ( ≥ 2.5 x upper limit normal [ ULN ] alanine aminotransferase , aspartate aminotransferase , gammaglutamyl transpeptidase , ≥ 2 x ULN creatinine ) . Elevations bilirubin due benign condition Gilbert 's syndrome exclusionary . 11 . Severe disease organ system . 12 . Local systemic complication pathological state require therapy corticosteroid and/or immunosuppressive agent . 13 . Type 1 diabetes . 14 . Glaucoma , family history glaucoma first degree relative . 15 . Known hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) , accord local privacy policy . 16. severe anemia ( &lt; 9 g/dL hemoglobin ) , leukopenia ( &lt; 2.5 x 109 white blood cell [ WBC ] /L ) , granulocytopenia ( &lt; 1.2 x 109 cells/L ) . 17 . Patients history pancolitis ( disease extend hepatic flexure beyond ) ≥ 8 year leftsided colitis ( disease confine leave colon [ i.e. , distal splenic flexure ] ) ≥ 15 year yet complete surveillance colonoscopy dysplasia/colorectal cancer screen within past year . 18 . Prior budesonide MMX treatment . 19 . Use oral corticosteroid include budesonide formulation within last 4 week prior randomization . 20 . Use rectal 5ASA corticosteroid formulation within last 2 week prior randomization . 21 . Use immunosuppressive agent within last 8 week prior randomization . 22 . Use antitumor necrosis factoralpha ( antiTNFα ) agents biologic therapy within last 3 month prior randomization . 23 . Participation experimental therapeutic study within 30 day randomization ( within last 3 month antiTNFα biologic agent study ) . Note : patient participate observationalonly study ( receive study therapy ) exclude . 24 . Any medical condition Principal Investigator 's opinion would make administration study drug study procedures hazardous patient , obscure interpretation adverse event ( AEs ) appropriate independent ethic committee/institutional review board .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Ulcerative Colitis</keyword>
</DOC>